MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias by Spinello, I et al.
ORIGINAL ARTICLE
MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute
myeloid leukemias
I Spinello
1, MT Quaranta
1, R Riccioni
1, V Riti
1, L Pasquini
1, A Boe
1, E Pelosi
1, A Vitale
2, R Foa `
2, U Testa
1 and C Labbaye
1
1Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita `, Rome, Italy and
2Department of
Cellular Biotechnologies and Hematology, Division of Hematology, ‘Sapienza’ University, Rome, Italy
CXCR4 is a negative prognostic marker in acute myeloid
leukemias (AMLs). Therefore, it is necessary to develop novel
ways to inhibit CXCR4 expression in leukemia. AMD3100 is an
inhibitor of CXCR4 currently used to mobilize cancer cells.
CXCR4 is a target of microRNA (miR)-146a that may represent a
new tool to inhibit CXCR4 expression. We then investigated
CXCR4 regulation by miR-146a in primary AMLs and found an
inverse correlation between miR-146a and CXCR4 protein
expression levels in all AML subtypes. As the lowest miR-
146a expression levels were observed in M5 AML, we analyzed
the control of CXCR4 expression by miR-146a in normal and
leukemic monocytic cells and showed that the regulatory miR-
146a/CXCR4 pathway operates during monocytopoiesis, but is
deregulated in AMLs. AMD3100 treatment and miR-146a over-
expression were used to inhibit CXCR4 in leukemic cells.
AMD3100 treatment induces the decrease of CXCR4 protein
expression, associated with miR-146a increase, and increases
sensitivity of leukemic blast cells to cytotoxic drugs, this effect
being further enhanced by miR-146a overexpression. Alto-
gether our data indicate that miR-146a and AMD3100, acting
through different mechanism, downmodulate CXCR4 protein
levels, impair leukemic cell proliferation and then may be used
in combination with anti-leukemia drugs, for development of
new therapeutic strategies.
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Introduction
Several mechanisms regulate the interaction of normal and
leukemic bone marrow (BM) stem/progenitor cells with the BM
microenvironment, consisting of extracellular matrix and the
stromal cells. This interaction has a key role in the control of
survival, proliferation, self-renewal, chemoresistance and mo-
bilization of stem/progenitor cells. Among the various mechan-
isms, the interaction between SDF-1a (also known as CXCL12)
and its receptor is crucial for directing homing and engraftment
of human hematopoietic stem cells into the BM after transplan-
tation in immunodeﬁcient mice.
1,2 Binding of SDF-1a induces
CXCR4 phosphorylation and internalization, and subsequent
incorporation into lipid rafts with generation of active cell
signalling, ultimately leading to changes in gene transcription
with consequent changes in survival, proliferation and migration
of stem/progenitor cells.
3 Several studies support the role of
CXCR4 and its ligand, SDF-1a, in the regulation of the normal
and leukemic stem cells motility in vivo,
4–6 in leukemic cell
survival and differentiation, and in the development of human
acute myeloid leukemia (AML) stem cells.
7–9 High level of
CXCR4 expression on the surface of AML blasts is associated
with poor relapse-free and overall survival
9–12 and may account
for resistance to antileukemic drugs.
6,13 Blockage of the CXCR4
receptor by the small molecular inhibitor AMD3100 is currently
being successfully employed to mobilize hematopoietic stem
cell from the BM into the peripheral blood
13 and to inhibit
growth and metastasis of experimental tumors in animal
models.
12 Another strategy to downregulate CXCR4 expression
in target cells is based on speciﬁc blocking of CXCR4 or SDF-1
expression at the mRNA level by employing small interfering
RNAs or an oligonucleotide antisense strategy.
14–16
MicroRNAs (miRs) are small non-coding RNAs that regulate
gene expression through translational repression;
16 recently, we
have identiﬁed CXCR4 as a target of miR-146a that may
represent a new tool to downmodulate CXCR4 expression at the
protein level in target cells.
17
Here we analyzed miR-146a and CXCR4 expression in primary
blast cells obtained from M1-M5 AML cases. We provide
evidence that in M1 to M5 AMLs, CXCR4 expression is regulated
by miR-146a through a mechanism similar to that observed in
leukemic cell lines and in normal megakaryocytes.
17 The absent/
low expression of miR-146a represents a major determinant of the
high CXCR4 expression observed in some AMLs, mainly
pertaining to the M3, M4 and, in particular, M5 subtypes.
Accordingly, we investigated and conﬁrmed the role of miR-
146a in regulating CXCR4 protein expression at protein level, in
normal and leukemic monocytic cells.
We then analyzed the effect of AMD3100 treatment, in
combination or not with miR-146a overexpression, on the miR-
146a/CXCR4 regulatory pathway in leukemic cells. AMD3100
treatment of leukemic cells impair cell proliferation, whereas the
CXCR4 protein level is downmodulated and miR-146a expression
increases. Importantly, AMD3100 treatment increases leukemic
blast cell sensitivity to anticancer drug treatment by downmodulat-
ing membrane CXCR4 protein levels, this phenomenon being
potentiated by miR-146a overexpression.
Altogether our data indicate that the miR-146a/CXCR4
regulatory pathway operates during monocytopoiesis and in
primary AMLs, but that it is deregulated in some AMLs. These
observations shed light on the molecular mechanisms regulating
CXCR4 expression by miR-146a in normal and leukemic cells.
Materials and methods
Primary AML blast cells
Primary AMLs were obtained after informed consent.
17 RNA and
protein samples were previously prepared as described.
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Human myelomonocytic and monocytic leukemic cell lines,
U937 and THP-1 respectively (American Type Culture Collec-
tion, Manassas, VA, USA), were grown in RPMI medium
supplemented with 10% fetal calf serum (Gibco, Carlsbad,
CA, USA). Human cord blood was obtained from healthy donors
after informed consent. Cord blood CD34
þ HPC puriﬁcation,
unilineage monocytic liquid cultures in BIT 9500 serum-free
medium (Stemcell Technologies Inc., Vancouver, BC, Canada)
supplemented with human low density lipoprotein (40mg/ml),
FLT3 ligand (100ng/ml), interleukin 6 (1mg/ml) and macro-
phage colony-stimulating factor (50ng/ml) were performed as
previously described.
19
For morphologic analysis, cells were smeared on glass slides
by cytospin centrifugation, stained with May–Grunwald Giemsa
and analyzed at 400 magniﬁcation under a microscope (Eclipse
1000; Nikon, Tokyo, Japan) equipped with a digital camera.
Monocytic differentiation of leukemic cells
U937 cells were cultured with 1a,25-dihydroxyvitamin D3,
VitD3 (250nM), whereas THP-1 cells were cultured with
tetradecanoyl phobol acetate (TPA) (32nM) (Sigma-Aldrich,
St Louis, MO, USA) for induction of monocytic differentiation/
maturation. Cell growth analysis and Mo membrane marker
(CD11b, CD14, CD18) expression by ﬂow cytometry analysis
were performed as described.
20
AMD3100, SDF-1a and drug treatment of cells
U937 and THP-1 cell lines were cultured at 50000 cells/ml and
treated with AMD3100 (10mM) (Sigma-Aldrich), added every
2 days of culture, then with or without cytosine arabinoside,
21
Ara-C (Sigma-Aldrich), at 1 and 3mM for 24–48h, compared
with cultures with Ara-C alone or without any treatment as
control (C). Cell growth, apoptosis and CXCR4 protein expres-
sion were then analyzed by growth curve, annexin-test (Annexin
V-FITC apoptosis detection kit, BD Pharmingen, San Diego, CA,
USA) and ﬂow cytometry analysis (FACS) respectively, as
described below. Blast cells from primary AML samples were
cultured for only 24h with (i) SDF-1a (100ng/ml) (Sigma-
Aldrich), or (ii) AMD3100 (1mM), or (iii) Ara-C (1mM)o r
doxorubicinhydrochloride (Sigma-Aldrich), Doxo, at 1mM,
alone or in combination as compared with cultures without
any treatment for control (C). The percentage of apoptotic cells
(annexin-V-positive cells) and FACS analysis of CXCR4 protein
level were analyzed. The murine stromal cell line MS5 was
obtained from ATCC. These cells were currently grown in
a-minimum essential medium. For chemotherapy sensitivity
experiments these cells were grown in 12-wells cell culture
plates (Costar, Corning, NY, USA) until the formation of a cell
layer; then, culture supernatant was removed and replaced with
leukemic cells (U937-E or U937-miR146a) resuspended in 1ml
of tissue culture medium.
CXCR4 mRNA analysis
Quantitative reverse transcription and real-time PCR analysis for
GAPDH and CXCR4 were performed using commercial ready-
to-use primers/probe mixes (Assays on Demand Products,
Applied Biosystems, Foster City, CA, USA), as previously
described.
17
MiR-146a expression analysis
Quantitative real-time PCR analysis of miR-146a was performed
by TaqMan technology, using the kit ABI PRISM 7700 DNA
Sequence Detection System speciﬁc for miR-146a reverse
transcription and PCR analysis (Applied Biosystems), according
to the manufacturer’s procedure and as previously described.
17
FACS
To evaluate total CXCR4 protein expression, cells were ﬁxed
and permeabilized with Permi-Fix (BD Pharmingen) before
incubation with either a phycoerythrin-conjugated anti-CXCR4
monoclonal antibody, clone 1245 (BD Pharmingen) or a control
phycoerythrin-conjugated monoclonal antibody of the same
isotype. Cells were analyzed using the FACSCAN ﬂow
cytometer and the Cell Quest software (BD Pharmingen) for
acquisition and analysis.
17 To evaluate CXCR4 membrane
expression, 20000 cell aliquots were washed in phosphate-
buffered saline and then labelled on the membrane using the
same anti-CXCR4-conjugated antibody described above and
ﬂuorescence emission was analyzed as described above.
Intracytoplasmic CXCR4 protein expression was then evaluated
by subtraction between total and membrane CXCR4 protein
levels. All experiments were performed with the same batch of
anti-CXCR4 conjugated antibody. The reported mean ﬂuores-
cence intensity indicates the ratio between the geometric mean
ﬂuorescence values observed in CXCR4 labeled cells and cells
labeled with a negative control, gated on FSC/ SSC dot plot to
select viable cells.
Enforced expression of miR-146a in U937 cells
The human miR-146a precursor cloned into a pCDH expression
lentivector, PMIRH146aPA-1 (System Biosciences (SBI),
Mountain View, CA, USA), was transfected into 293TN
producer cells with the pPACKH1 packaging Plasmid mix,
LV500A-1, (SBI), using Lipofectamine and Plus Reagents
(Invitrogen, Carlsbad, CA, USA) to produce pseudoviral
particles. The pseudoviral titer was estimated to perform the
transduction of the packaged lentivector expression constructs:
(i) the empty pCDH expression lentivector (pCDH-empty,
pCDH-E) used for internal control; (ii) the PMIRH146aPA-1
construct referred as (pMIRNA-146a), in the target U937 cells,
according to the SBI manufacturer’s instructions. Infected-U937
cells were selected for copGFP expression by cell sorting
analysis. Stable transduced cell lines, U937-pMIRNA-146a
(U937-miR146a) and U937-pCDH-E (U937-E), were then
maintained in RPMI/fetal calf serum 10%. MiR-146a over-
expression was controlled by speciﬁc miR-146a real-time PCR
analysis (Applied Biosystems) in U937-miR146a cells as
compared with control U937-E and U937 wild-type (wt) cells.
Results
MiR-146a and CXCR4 expression in AML samples
We investigated miR-146a and CXCR4 expression among 38
AMLs mainly pertaining to ﬁve subgroups from M1 to M5 FAB
subsets (7 M1; 7 M2; 6 M3; 11 M4; 7 M5), as compared with
normal CD34
þ HPCs.
The levels of miR-146a expression analyzed by quantitative
real-time PCR were quite heterogeneous for each group of FAB-
classiﬁed AMLs; however, despite this heterogeneity lower miR-
146a expression was detected in the M4/M5 subtypes, as
compared with higher miR-146a expression detected in normal
CD34
þ HPCs (Figure 1a). In AMLs, a high CXCR4 membrane
protein expression, as evaluated by FACS analysis, has been
mostly associated with M4 and M5 AMLs;
9–11 furthermore, we
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of M4/M5 AMLs as compared with M1/M2 AMLs (Figure 1b).
Indeed, we found a highly signiﬁcant inverse correlation
between miR-146a expression and CXCR4 membrane protein
level, indicative of a posttranscriptional control of gene
expression; in fact, the plotting of miR-146a and CXCR4 protein
levels showed that these two parameters are inversely related
(r
2¼0.45; P¼0.0001) (Figure 1d). These data strongly suggest
that the regulatory network involving miR-146a regulation of
CXCR4 protein expression could operate in primary AML
samples. It is also of interest to note the following: (i) a total
absence of miR-146a expression was observed in 8/38 AML
cases, all pertaining to the M3, M4 and M5 subtypes; (ii) some
M1 and M2 AMLs express membrane CXCR4 at high levels,
associated with a low miR-146a expression.
We also analyzed CXCR4 mRNA expression level as
compared with CXCR4 protein levels in AML samples (Figures
1c and b). Our results showed a correlation between CXCR4
mRNA and CXCR4 protein level (Pp0.05) (Figure 1e), however,
less signiﬁcant than that observed between miR-146a and
CXCR4 protein expression.
Altogether, our data indicate that in primary AML samples CXCR4
expression is under, both, transcriptional and posttranscriptional
control. Indeed, M4 and M5 AMLs expressing the highest level of
CXCR4 protein, expressed also miR-146a at lower level.
MiR-146a and CXCR4 expression in unilineage
Mo culture
CXCR4 expression in myelomonocytic leukemias M4/ M5
prompted us to evaluate CXCR4 at the mRNA and protein
level, and miR-146a expression in human cord blood CD34
þ
HPCs induced in serum-free suspension culture to unilineage
differentiation and maturation through the Mo pathway.
19,20 Mo
proliferation and differentiation were monitored by cell growth
(Figure 2a) and increasing expression of CD11b antigen
(Figure 2b).
CXCR4 mRNA expression is high in CD34
þ HPCs (day 0)
then is rapidly downmodulated during the ﬁrst days of culture
(days 0–2), being progressively lower from day 5 onwards,
during Mo differentiation/maturation (Figure 2c). Conversely,
CXCR4 membrane (Figure 2d) and total (not shown) protein
expression is low at days 0–2 but is thereafter markedly
upregulated, with a peak at day 5 and remaining constant
through day 9, when it tends to decrease again from day 9 to 16
of culture (Figure 2d). In the same Mo cultures, miR-146a
expression level is high in the ﬁrst days of culture (days 0–2),
then it is downmodulated (days 2–5), increasing thereafter
during Mo differentiation (days 5–16) (Figure 2e). The rise of
CXCR4 membrane and total proteins, in the presence of a
decreased mRNA, suggests that the sharp decline of miR-146a
could effectively unblock CXCR4 mRNA translation.
Overall, during Mo proliferation and differentiation, miR-146a
expression is inversely related to the CXCR4 protein level (Figures
2d and e). The results hence suggest a post-transcriptional control of
miR-146a on CXCR4 protein level, without excluding a coupled
transcriptional control of CXCR4 protein level in this lineage.
MiR-146a overexpression reduces CXCR4 expression in
U937 cells, whereas VitD3 or TPA-induced monocytic
differentiation of U937 or THP-1 cells increases
miR-146a expression and inhibits CXCR4 protein expression
To strengthen the link between miR-146a and CXCR4 expres-
sion in the Mo pathway, we used U937 cells as a model of
Vitamin D3 (VitD3)-inducible Mo differentiation and evaluated
Figure 1 High level of CXCR4 membrane protein expression is
correlated with a low level of miR-146a expression in AMLs.
(a) Quantitative real-time (qRT)-PCR analysis of miR-146a expression
levels in primary AML samples (from M1 to M5 of FAB classiﬁcation)
compared with normal CD34
þ HPCs. (b) FACS of CXCR4 membrane
protein expression levels in the same AML samples. (c) RT-PCR
analysis of CXCR4 mRNA expression in AMLs samples. (d) Negative
correlation between CXCR4 levels and miR-146a expression
(Pp0.0001). (e) Direct correlation between CXCR4 mRNA and
protein levels (Pp0.05).
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in CXCR4 expression affect proliferation, differentiation and
maturation of these cells.
Lentivectors, such as pMIRNA-146a to increase miR-146a
expression level and pCDH-E, the empty vector used as a control,
were prepared to infect U937 cells. U937-pMIRNA-146a cells
(U937-miR146a) and U937-pCDH-E control cells (U937-E) were
then cultured as compared with U937 wt cells.
MiR-146a overexpression in U937 cells induces a decrease of
CXCR4 protein, as evidenced through analysis of total and
membrane CXCR4 expression levels (Figure 3e). In control cells
U937-E or U937 wt (not shown), VitD3 treatment impairs cell
proliferation (Figure 3a) and increases CD11b (Figure 3b) and
CD14, CD18 (not shown) Mo marker expression. We also found
that VitD3 upmodulates miR-146a expression (Figure 3d),
whereas CXCR4 protein expression decreases (Figure 3e), with-
out any signiﬁcative modulation of CXCR4 mRNA expression
(Figure 3c). These data mimic those observed in HPCs induced
to Mo unilineage differentiation and maturation (Figures 2c–e),
indicating that VitD3-induced U937 cells represent a useful
model system to evaluate the role of the miR-146a/CXCR4
interaction during Mo differentiation.
FACS evaluation revealed that in VitD3-treated (from day 0 to 7)
or untreated U937 cells (day 0), CXCR4 was downmodulated by
miR-146a overexpression (Figure 3e), whereas we did not
observe any signiﬁcant modulation of CD11b (Figure 3b) and
CD14 or CD18 (not shown) Mo markers, as compared with
U937-E and wt control cells (Figure 3b). However, miR-146a
clearly impairs cell proliferation (miR-146a) and exerts a
synergistic effect in combination with VitD3 (miR-146a þ
VitD3) to decrease the proliferation rate growth of U937-
miR146a cells, as compared with control cells (Figure 3a). Thus,
miR-146a diminishes CXCR4 protein expression and impairs Mo
proliferation of U937 cells, without any apparent modulation of
Mo differentiation.
However, we evaluated the effect of miR-146a overexpres-
sion in U937 cells induced to monocytic differentiation using a
different monocytic inducer, TPA. We treated U937-miR146a
cells, as compared with control cells (wt and U937-E) by TPA
and observed (a) a marked inhibitory effect on cell growth,
major in U937-miR146a cells, as compared with U937-wt
(Po0.05) and U937-E (Po0.05) cells (data not shown); (b) a
downmodulation of CXCR4 membrane protein expression
(Figure 3h), concomitantly with the induction of Mo membrane
differentiation markers: interestingly, CD11b and CD14 expres-
sion was lower in U937-miR146a than in control cells U937-wt
(for both Po0.05) and U937-E (for both Po0.05) cells
(Figures 3f and g).
Altogether, these data indicate that using another inducer of
Mo differentiation, miR-146a overexpression inhibits cell
growth and Mo differentiation of U937 cells treated by TPA.
We also used another cellular model of Mo differentiation,
TPA-induced THP-1 cells to analyze cell growth, Mo differ-
entiation, CXCR4 membrane protein expression and miR-146a
expression, as compared with untreated THP-1 cells (Supple-
mentary Figure S1). Altogether, our data were in line with those
observed during VitD3-induced Mo differentiation of U937 cells
(Supplementary Figure S1).
Furthermore, we could not detect any modulation of previously
described miR-146a target genes, such as tumor necrosis factor
receptor-6 (ref. 22) (data not shown), indicating CXCR4 as a
speciﬁc target of miR-146a in VitD3- or TPA- treated U937 cells.
AMD3100 treatment impairs leukemic cell proliferation
and differentiation, induces miR-146a expression and
inhibits CXCR4 expression
AMD3100 is a non-peptide antagonist of the CXCR4 receptor
currently used to inhibit CXCR4 function and to mobilize
hematopoietic stem cells.
12 Here we analyzed the response to
Figure 2 MiR-146a and CXCR4 expression in puriﬁed CD34
þ HPCs induced to monocytic (Mo) differentiation. (a, b) CD34
þ HPCs (day 0)
proliferation and differentiation were controlled, respectively, by growth curve analysis (a) and expression of CD11b (b). (c) Real time PCR analysis
of CXCR4 mRNA expression in HPCs grown in liquid-phase unilineage Mo cultures. (d) FACS of CXCR4 membrane protein expression in HPCs
during unilineage Mo cultures. The geometric mean ﬂuorescence intensity is indicated. (e) Real time PCR analysis of miR-146a expression in HPCs
during Mo differentiation. (a, b) One representative experiment out of three is shown. (c–e) The results of three independent experiments
(mean±s.e.m. values) are shown.
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control cells U937-E and U937-wt.
We ﬁrst observed a decrease of the proliferation rate of
U937-E cells upon AMD3100 treatment, as compared with
untreated cells (Figure 4a), which is further enhanced by
miR-146a (Figure 4a). The cell growth inhibition induced by
AMD3100 is related to a reduced cell cycling (the proportion of
SþG2þM cells was at day of culture: in U937-wt C 48.5±3.7
vs AMD3100 41.2±3.3, Po0.03; in U937-E 47±3.5 vs
AMD3100 41.8±3.6, P¼0.05; in U937-miR-146a C
44.9±3.5 vs 38±3.7, Po0.05) (mean values±s.d. observed
in ﬁve separate experiments).
In line with previous studies,
6,7 short AMD3100 treatment
(days 0–2) decreases CXCR4 protein level expressed on the
leukemic cell membrane (Figure 4d, right panel). Surprisingly,
upon longer AMD3100 treatment (days 2–7) of control cells
(U937-E and wt), total CXCR4 protein expression is down-
modulated, as detected by FACS analysis in permeabilized cells
(Figure 4d, left panel), whereas miR-146a increases (Figure 4c),
without any signiﬁcative modulation of CXCR4 mRNA level
(Figure 4b), as compared with untreated cells (day 0). We also
investigated the modulation of CXCR4 protein expression in
U937 cells exposed to acute treatment (1–4h) with AMD3100.
Exposure to AMD3100 elicited a rapid downmodulation of
CXCR4 membrane protein expression, due in large part to
receptor internalization, a clearly detectable event after 1h of
incubation (Figure 4e). The extent of CXCR4 internalization
induced by AMD3100 was comparable in all, U937-wt, U937-E
and U937-miR146a, cell lines (Figure 4f).
We also show that AMD3100, used in a chronic treatment of
leukemic cells, induces miR-146a expression (Figure 4c) and
enhances the effects previously observed by miR-146a over-
expression in leukemic cells, such as the decrease of CXCR4
protein level (Figure 4d) and leukemic cell growth inhibition
(Figure 4a).
Although we explored a possible effect of AMD3100
treatment on Mo differentiation of U937 cells in the absence
of a Mo differentiation inducer, we found that AMD3100 alone
was unable to induce any signiﬁcant change of morphological
features and CD11b, CD14 membrane antigen expression levels
(Supplementary Figures S2a, b: C). We then evaluated the effect
of AMD3100 treatment on Mo differentiation of U937 cells,
induced by chemical inducers, such as, TPA (Supplementary
Figures S2a, b, c: TPA) and VitD3 (Supplementary Figures S2d,
e, f: VitD3).
Our data showed that during TPA-induced Mo differentiation
of U937 cells, CXCR4 membrane protein expression is down-
modulated, whereas miR-146a is upmodulated (Supplementary
Figure 3 Overexpression of miR-146a in U937 cells downregulates CXCR4 protein expression and impairs cell growth induced by vitamin D3 or
TPA. (a) Growth curve of U937-miR146a (miR-146a) and U937-Empty (E) cells grown either in the absence or in the presence of vitamin D3
(VitD3). (b) FACS of CD11b expression in U937-miR146a (miR-146a) cells, as compared with control cells U937-wt (wt) and U937-E cells (E),
treated with VitD3 to induce Mo differentiation, compared with VitD3-untreated cells (day 0). (c, d) Quantitative real-time PCR analysis of CXCR4
mRNA and miR-146a expression were performed at the indicated days, in U937-miR146a cells as compared with control cells (wt and E), treated
by VitD3 for Mo differentiation compared with untreated cells (day 0). (e) FACS of CXCR4 protein expression during VitD3 treatment of U937-
miR146a and control cells (wt and E) compared with untreated cells (day 0). CXCR4 protein expression was evaluated at both, total (left panel) and
membrane (right panel) level, on permeabilized and intact cells, respectively. (f, g) FACS of CD11b and CD14 expression in U937-miR146a
(miR-146a) cells, as compared with control cells U937-wt (wt) and U937-E cells (E), treated with TPA to induce Mo differentiation, compared with
TPA-untreated cells (day 0). (h) FACS of CXCR4 membrane protein expression during TPA treatment of U937-miR146a and control cells (wt and E)
compared with untreated cells (day 0). (a, b) One representative experiment out of three is shown. (c–h) The results of three independent
experiments (mean±s.e.m. values) are shown. (e–h) The geometric MFI is shown as mean±s.e.m. values from three independent experiments.
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treated cells (Supplementary Figure S2f). However, AMD3100
treatment of VitD3-treated cells only slightly impaired Mo
differentiation as assessed by morphological features (not
shown) and CD11b, CD14 Mo markers expression analysis
(Supplementary Figure S2d; Figure 2e), whereas AMD3100
treatment of TPA-treated cells induced a marked inhibition of
Mo differentiation, as shown by morphology and CD11b, CD14
expression analysis (Supplementary Figure S2a; Figure 2b).
Similar results were observed when we treated THP-1 cells with
TPA to induce Mo differentiation, in addition with AMD3100
treatment (Supplementary Figure S1: TPAþAMD3100).
It is also of interest to note that in U937-miR146a cells,
AMD3100-mediated inhibition of U937 TPA-induced Mo
differentiation is major than that observed in control U937-E
and U937-wt cells (Supplementary Figure S2a).
Altogether, these data indicate that AMD3100 treatment has
an effect on proliferation and differentiation of monocytic
leukemic cell lines.
MiR-146a and AMD3100 downmodulate CXCR4
protein expression and stimulate the drug sensitivity
of leukemic cells
We investigated further the effect of AMD3100 for 24h, in
combination or not with an anti-leukemic drug, such as Ara-C
21
(Figure 5a) or Doxorubicin
21 (not shown) on leukemic cell
proliferation. Our data indicate that, as expected, Ara-C induces
a dose-independent growth inhibition of both U937-miR146a
and U937-E control cells (Ara-C 1–3mM), whereas AMD3100
alone has a mild inhibitory effect on the growth of these cells
(Figure 5a, AMD). However, the effect of AMD3100 used in
combination with Ara-C on the growth inhibition of leukemic
cells is greater than that previously observed with Ara-C alone in
both U937-miR146a and control U937-E cells (Figure 5a,
AMDþAra-C). Indeed miR-146a overexpression enhances, at
a mild but signiﬁcant level, the effect of AMD3100 used in
combination with Ara-C, as a major growth inhibition of U937-
miR146a cells is observed in combination treatment as com-
pared with U937-E control cells (Figure 5a, U937-miR146a).
Figure 4 AMD3100 treatment, downmodulates CXCR4, activates miR-146a and impairs leukemic cell proliferation. (a) Growth curve of U937-
miR146a (miR-146a) and control U937-Empty (E) cells treated with AMD3100 added every two days in cultures, compared with untreated cells.
(b) Quantitative real-time PCR analysis of CXCR4 mRNA and (c) miR-146a expression were, respectively, performed on the indicated days, in
U937-miR146a cells as compared with control cells (wt and E), treated by AMD3100 compared with untreated cells (day 0). (d) FACS analysis of
CXCR4 protein expression at sequential days during AMD3100 treatment of U937-miR146a and control cells (wt and E) compared with untreated
cells (day 0). CXCR4 protein expression was evaluated at both, total (left panel) and membrane (right panel) level, on permeabilized or intact cells,
respectively. The geometric MFI is shown as mean±s.e.m. values from three independent experiments. (e) FACS analysis of total and membrane
CXCR4 protein expression, as compared with (f) internalized CXCR4 protein levels during acute (1 and 4h) AMD3100 treatment of U937-miR146a
and control wt and E cells. (a) One representative experiment out of three is shown. (b–f) Results of three independent experiments are shown
(mean±s.e.m. values).
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seem to be related to induction of cell differentiation, as
indicated by analysis of cell morphology and of membrane
differentiation antigens (data not shown).
Altogether, we show that AMD3100 treatment increases the
drug sensitivity of leukemic cells and miR-146a, moderately, but
signiﬁcantly enhances this effect.
Combined CXCR4 inhibition, mediated by miR-146a
and AMD3100, reduces stromal-induced protection
against chemotherapy
Previous studies have shown that BM stromal cells are able to
modulate the chemosensitivity of leukemic blasts through
mechanisms involving CXCR4/SDF-1a, VLA-4/ﬁbronectin and
other mediators/receptors.
7 The growth in vitro of leukemic
cells, on the stromal MS5 cells in part mimics this BM
microenvironment, affecting the sensitivity of leukemic cells to
antineoplastic agents.
7 We then grew U937-E and U937-
miR146a cells in the presence of a layer of MS5 cells
(Figure 5b, right panel), as compared with liquid cultures (left
panel), and evaluated their sensitivity to Ara-C, by analyzing the
induction of apoptosis in U937-E and U937-miR146a cells
(Figure 5b). We showed that (i) the sensitivity of both U937-E
and U937-miR146a cells to Ara-C, particularly when added at
1mM, is markedly reduced when cultured on MS5 cells;
however, this decrease is more pronounced in U937-E than in
U937-miR146a cells; (ii) AMD3100 in part rescued this
decrease in drug sensitivity: this rescue being more pronounced
in U937-miR146a than in U937-E cells (Figure 5b). These results
indicate that the combined downmodulation of CXCR4 expres-
sion mediated by miR-146a overexpression and AMD3100
treatment is more efﬁcacious than AMD3100 treatment alone to
restore chemosensitivity of leukemic cells when these cells are
grown in the presence of stromal cells.
Altogether, our data suggest that inhibition of CXCR4
expression by miR-146a overexpression and AMD3100 repre-
sent a strategy to enhance the drug sensitivity of leukemic cells.
AMD3100 enhances the sensitivity of CXCR4-positive
AMLs to chemotherapy in vitro
We investigated further the functional role of CXCR4 blockade
by AMD3100 on primary AMLs. We ﬁrst selected ﬁve primary
AMLs (two M4, two M5 and one M2) for both their high levels of
Figure 5 miR-146a and AMD3100 treatment downmodulates CXCR4, enhances the drug sensitivity of leukemic cells and reduces stromal-
induced protection against chemotherapy. (a) Growth inhibition of U937-E and U937-miR146a cells after treatment (0–2 days) with AMD3100
(AMD) (10mM) in combination, or not, with Ara-C (1 or 3mM), as compared with untreated cells (C); (b) Induction of apoptosis in U937-E and
U937-miR146a cells grown in liquid cultures as in a, either in the absence (left panel) or in the presence (right panel) of a layer of MS5 stromal
cells; (c) FACS of CXCR4 surface protein expression in two representative primary AML samples treated 24h with AMD3100 (1mM) (white shadow)
or not untreated (gray shadow). Fluorescence histograms immunoglobulin G-phycoerythrin (IgG-PE) and CXCR4-PE indicate, respectively,
PE-conjugated control mouse IgG labelling and surface PE-conjugated CXCR4 labelling of both AML samples. (d) Percentage of apoptotic cells,
indicated as annexin-V-positive cells, is detected by FACS performed in ﬁve primary AML samples cultured at 24h: (i) without any treatment as a
control (C); or with (ii) 100ng/ml of the CXCR4 ligand, SDF-1; (iii) or 1mM AMD3100 (AMD); (iv) or 1mM Ara-C; (v) or 1mM Doxorubicin (Doxo),
(iv and v) alone or in combination with AMD. The bars reported in the scattergrams represent the mean values. *Po0.05; **Po0.01.
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apoptosis, to analyze the ability of AMD3100 to compete
with the anti-CXCR4 monoclonal antibody 12G5 for CXCR4
binding.
22,23 Our data show that, as previously observed in
leukemic cells using high concentration (10mM) of AMD3100
(Figure 5a), AMD3100 treatment, at lower concentration such as
1mM, induces a marked decrease of surface staining of CXCR4
protein, of our selected primary AMLs (Figure 5c).
We then analyzed whether the inhibition of CXCR4 by acute
AMD3100 treatment (24h) modulates the sensitivity of AML
blast cells to chemotherapeutic agents, by treating the CXCR4-
positive AML samples with AMD3100 in combination, or not,
with chemotherapy (Ara-C or Doxorubicin, Doxo) for 24h
(Figure 5d). Our data indicate that SDF-1a treatment did not
signiﬁcantly modify the rate of spontaneous apoptosis of AML
blasts; in contrast, AMD3100 induces a slight but signiﬁcant
increase of the percentage of apoptotic cells as compared with
untreated cells (C) (Figure 5d). However, AMD3100 treatment
enhances signiﬁcantly Ara-C or Doxorubicin-induced apoptosis
of the leukemic blast cells, as compared with untreated control
cultures, whereas SDF-1a reduces it (Figure 5d).
Altogether, our data show that acute AMD3100 treatment of
primary AML blast cells downmodulates surface CXCR4 protein
expression and enhances the sensitivity of AML blasts to
chemotherapy-induced apoptosis.
Discussion
We have recently identiﬁed the mechanism of CXCR4 regula-
tion by miR-146a targeting in megakaryocytic cells.
17 Previous
studies have shown that a high CXCR4 expression level is a
negative prognostic marker in AMLs,
2,9–11 independently of
some other negative prognostic factors.
10,11,24 However, the
molecular mechanisms responsible for the high CXCR4 expres-
sion observed in some AML cases are currently unknown.
Here, we have investigated miR-146a expression as com-
pared with CXCR4 expression levels in AMLs and found that the
miR-146a/CXCR4 regulatory pathway seems to operate in
various AML subtypes independently of the differentiation
capacities of these cells. Altogether, our study suggests that
the absence of or low miR-146a expression could represent one
of the mechanisms responsible for the elevated CXCR4
expression in leukemic cells. Indeed, high CXCR4 expression
was associated with low miR-146a expression in all AML
subtypes, including M1, M2, M3, M4 and M5. In line with
previous reports,
9,24 CXCR4 expression was particularly high in
myelomonocytic (M4) and monocytic (M5) AMLs. Therefore, it
seemed of particular interest to explore the expression and
regulation of the miR-146a/CXCR4 pathway in the normal
monocytic lineage. The importance of this issue is also
supported by a recent study showing that SDF-1a,b ya n
autocrine/paracrine mechanism, regulates a peculiar set of the
genetic program of macrophage differentiation.
25 In CD34
þ
HPCs cultures undergoing monocytic differentiation, we show
that CXCR4 mRNA is downmodulated during monocytopoiesis,
whereas CXCR4 protein expression is markedly upmodulated.
This ﬁnding strongly suggests that unblocking CXCR4 transla-
tional is one of the main molecular mechanisms controlling
CXCR4 protein levels during monocytopoiesis. In line with this
hypothesis, we observed that miR-146a levels are clearly
downmodulated during the initial stages of monocytic differ-
entiation. At later, terminal stages of monocytic differentiation,
miR-146a markedly increases, while CXCR4 protein levels
decrease.
An autocrine SDF-1a/CXCR4 loop was recently shown to be
involved in the control of monocyte to macrophage differentia-
tion.
25 Furthermore, previous studies have shown a possible
effect of AMD3100 on leukemic cell differentiation.
6 Our results
showed that a reduction of CXCR4 expression/function does not
modify the spontaneous differentiation of leukemic cells, while
it impairs the monocytic differentiation of these cells triggered
by chemical inducers, particularly by TPA.
Altogether we show that in normal monocytopoiesis miR-
146a regulates CXCR4 expression, as previously reported by our
group in the megakaryocytic lineage.
17 According to these
ﬁndings, a low or absence of miR-146a expression, often
observed among AMLs, may represent a key factor responsible
for the high CXCR4 expression in these cells. Furthermore, our
previous
17 and present ﬁndings are in line with studies that have
shown that miR-146a expression is deregulated in leukemia.
26–28
Garzon et al.
26 in a screening carried out on 122 untreated
AMLs showed that miR-146a is one of the miRNAs most
downmodulated in AML blasts, compared with normal CD34
þ
cells. M4/M5 AMLs, with MLL rearrangement and with the
majority of leukemic cells being monoblasts, display miR-146a
levels clearly lower than other AMLs.
27 Finally, miR-146a was
found to be markedly downmodulated in 5q- syndrome CD34
þ
cells, compared with normal CD34
þ cells.
28 Importantly,
knockdown of miR-146a in mouse hematopoietic stem cells
resulted in the development of some hematological abnormal-
ities, such as neutropenia and megakaryocytic dysplasia,
typically observed in myelodysplastic syndromes.
28 Further-
more, knockdown of miR-145 and miR-146a results in long-
latency myeloid leukemia in mice.
29
Why high CXCR4 expression is a negative prognostic factor
for AML patient survival after chemotherapy remains to be
elucidated. This phenomenon could be related, to a certain
extent, to the regulation of AML cell migration by SDF-1a/
CXCR4.
30 However, recent reports suggest an alternative
mechanism related to the effect of CXCR4 signalling on drug
sensitivity. In fact, evidence has been provided that CXCR4
activation by SDF-1a (either as soluble chemokine or as stromal
cell-bound chemokine) reduces the sensitivity of AML blasts to
various anti-leukemic drugs, whereas an opposite effect is
elicited by CXCR4 inhibitors.
6,7,31,32
In the present study we have explored the effect of a CXCR4
inhibitor, AMD3100, recently registered as a hemopoietic stem
cell mobilizing agent, on AML blasts. In line with a previous
report,
30 acute exposure of leukemic cells to this agent
determines the rapid and massive downmodulation of surface
CXCR4 due to receptor internalization, although the total
receptor expression remains virtually unmodiﬁed.
32 However,
prolonged exposure of leukemic cells to AMD3100 induces a
decrease of total CXCR4, a phenomenon possibly related to
intracellular receptor degradation and also to reduced receptor
translation. In fact, we observed that AMD3100 induces an
increased expression of miR-146a. Furthermore, in line with
previous studies,
7 we observed that disruption of the CXCR4/
SDF-1a interaction by the CXCR4 inhibitor AMD3100 clearly
increases the sensitivity of leukemic cells to Ara-C. This effect
was further potentiated in leukemic cells where CXCR4
expression is decreased by miR-146a overexpression. These
ﬁndings suggest that the optimal therapeutic effect potentially
deriving from inhibition of the CXCR4/SDF-1a axis requires a
combined effect both at the level of CXCR4 content
(that is, decreasing it by miR-146a overexpression) and of
SDF-1a/CXCR4 interaction (that is, inhibiting this interaction
using AMD3100 or similar agents). In this context, it is of interest
to note that a recent study reported the synergistic antileukemic
CXCR4 control by miR-146a and AMD3100 in leukemia
I Spinello et al
8
Blood Cancer Journalactivity of a histone deacetylase inhibitor that markedly
upmodulates miR-146a levels and AMD3100.
33
In addition to CXCR4, miR-146a was shown to target in
hematopoietic cells other mRNAs and particularly those
encoding some factors involved in innate immune signalling,
such as tumor necrosis factor receptor-6,
22 toll-like receptor 2
34
and through these mechanisms it seems to have a critical role for
endotoxin-induced tolerance by monocytes.
35 Although in our
cellular models we have failed to demonstrate an effect of miR-
146a overexpression on tumor necrosis factor receptor-6 protein
expression levels, we cannot exclude that other miR-146a
targets may have a relevant role to explain its effect at the level
of AMLs.
Altogether, our study indicates that a low miR-146a expres-
sion may contribute to the elevated CXCR4 expression observed
in some AMLs. Furthermore, modulating the levels of miR-146a,
as also recently shown for some solid tumors, including breast
cancer
36 and pancreatic cancer,
37 could have a therapeutic
potential, together with CXCR4 inhibitors, to improve drug
sensitivity of leukemia cells.
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